 |
|
|
 |
Dieters beware: Hidden carbs in familiar OTCs may hinder weight-loss efforts
Millions of Americans have made carb counting a central tenet of their weight-loss efforts, but while the increasing number of low-carb foods, beverages and restaurant menu items trumpet their carb contents, undisclosed or "hidden" carbs in products such as over-the-counter medications risk undermining the weight-loss efforts of even the most-fervent carb-counters.
more
|
|
Clinical trial of a new TB vaccine in the U.S. begins; New vaccine may prove more potent than 100-year-old current vaccine
The Aeras Global TB Vaccine Foundation and the David Geffen School of Medicine at UCLA announced on 17 February 2004 that they have begun the first clinical trial of a live recombinant tuberculosis vaccine in the U.S. Six volunteers were inoculated today with the new vaccine at the Center for Vaccine Development, St. Louis University, Missouri, under the direction of Dr. Daniel F. Hoft. Volunteers are also being recruited at another trial site in Winston-Salem, North Carolina, by Piedmont Medical Research Associates under the direction of Dr. Thomas W. Littlejohn III.
more
|
|
Featured NCI clinical trial: Antiangiogenic therapy for high-grade, recurrent brain tumors
Glioma, a type of brain cancer, is the most common primary tumor of the central nervous system. Surgery is often used to treat gliomas. Sometimes, however, surgery fails to cure the disease. In these cases, doctors may turn to radiation or chemotherapy. A chemotherapy drug known as LY317615 may stop the growth of gliomas by halting blood flow to the tumor, a process called antiangiogenesis.
more
|
|
|
|
Combating counterfeit drugs: A Report of the Food and Drug Administration (PDF)
The counterfeiting of currency and consumer products are common problems that plague governments and manufacturers around the world, but the counterfeiting of medications is a particularly insidious practice. Drug counterfeiters not only defraud consumers, they also deny ill patients the therapies that can alleviate suffering and save lives. In some countries the counterfeiting of drugs is endemic -- with some patients having a better chance of getting a fake medicine than a real one. In many more countries, counterfeit drugs are common. In the United States, a relatively comprehensive system of laws, regulations, and enforcement by Federal and state authorities has kept drug counterfeiting rare, so that Americans can have a high degree of confidence in the drugs they obtain through legal channels. In recent years, however, the FDA has seen growing evidence of efforts by increasingly well-organized counterfeiters backed by increasingly sophisticated technologies and criminal operations to profit from drug counterfeiting at the expense of American patients. more
|
|
Outcome Reduction with Initial Glargine Intervention (ORIGIN) trial enters active recruitment phase
Earlier this week, Aventis announced that the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial has entered the active recruitment phase and has enrolled over 400 patients to date. The trial is the first major clinical study to help determine whether the use of Lantus(R)(insulin glargine [rDNA origin] injection) -- a 24-hour basal insulin analogue -- can reduce the incidence of cardiovascular events such as heart attack and stroke in people with early diabetes or pre-diabetes who are at high risk for cardiovascular disease. The five-year trial, led by Dr. Hertzel Gerstein and Dr. Salim Yusuf at the Population Health Research Institute, McMaster University and Hamilton Health Sciences in Hamilton, Ontario, Canada, and sponsored by Aventis, will include 10,000 participants from 600 sites in more than 35 countries. more
|
|
Prescribing information: Lantus(R) (insulin glargine [rDNA origin] injection) (PDF)
Lantus® is a recombinant human insulin analog that is a long-acting, parenteral blood-glucose-lowering agent. The activity of Lantus results in a relatively constant concentration/time profile over 24 hours with no pronounced peak. This profile is what allows Lantus to be dosed once a day as a patient's basal insulin. Lantus provides a continuous level of insulin, similar to the slow, steady (basal) secretion of insulin provided by the normal pancreas.
more
|
|
CDC Verb campaign is motivating youth to get active
The Centers for Disease Control and Prevention (CDC) today released results from a survey that indicate physical activity among the nation’s youth is increasing as a result of a national youth media campaign launched by the agency in 2002. The award winning multicultural campaign known as Verb had one of the largest effects, a 34 percent increase, in weekly free-time physical activity sessions among 8.6 million children ages 9-10 in the United States. more
|
|
|
